Form 4 for NGNE Neurogene Inc.
Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-22 · accession 0001404644-24-000113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-25 | 2024-11-22 | NGNE | Cvijic Christine Mikail | Pres, CFO | P - Purchase | $20.48 | +24.0K | 76.8K | +45% | +$491.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | P | A | 24,000 | $20.48 | 76,844 | D | — | — | (F1) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.33 to $20.92, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. (F2) Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic. |